IC
RLMD icon

Ikarian Capital’s Relmada Therapeutics RLMD Stock Holding History

Ikarian Capital’s Portfolio RLMD Stock Details RLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-775,300
Closed -$28.7M – 103
2022
Q3 		$28.7M Buy
775,300
+493,000
+175% +$13.7M 5.72% 1
2022
Q2 		$5.36M Buy
+282,300
New +$6.16M 0.98% 34

Other funds holding RLMD

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $273M AUM
SSC
Spruce Street Capital New York $416M AUM
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Ikarian Capital's RLMD Position: Q1 2026 in Review

Ikarian Capital reduced its Relmada Therapeutics (RLMD) stake by 12% in Q1 2026, selling an estimated $1.8M and leaving 2,688,359 shares worth $18.7M. The position accounts for 1.52% of the portfolio, ranked #15.

Ikarian Capital first reported a position in RLMD in Q1 2020 and has held it in 20 quarters since. 103 funds tracked by Wall St. Rank hold RLMD as of Q1 2026.

  • Ikarian Capital held 2,688,359 shares of Relmada Therapeutics worth $18.7M as of Q1 2026.
  • Ikarian Capital sold 380,000 Relmada Therapeutics shares in Q1 2026, an estimated $1.8M.
  • Relmada Therapeutics made up 1.52% of Ikarian Capital's portfolio in Q1 2026, its #15 holding.
  • Ikarian Capital first reported a position in Relmada Therapeutics in Q1 2020 and has held it in 20 quarters since.
  • 103 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q1 2026.

Based on Ikarian Capital's 13F filing for Q1 2026, filed 15 May 2026.